Hyperthyroidism (Graves Disease)

Why Type 2 amiodarone-induced thyrotoxicosis is correct

• Amiodarone is about 37% iodine by weight, and a 200 mg daily dose releases roughly 7 mg of free iodide, some 50 times the daily requirement, so thyrotoxicosis appearing years into therapy is a drug effect until proven otherwise. The drug causes it by two different mechanisms, the hormone levels look the same in both, and the type has to be settled by the gland itself before anything is added.
• Type 2 disease is a direct drug toxicity to follicular cells: the gland is destroyed rather than driven, preformed hormone leaks out of it, and new synthesis stops. A structurally normal, painless, non-enlarged gland with absent intrathyroidal flow on color-flow Doppler is the signature, because a gland that is not synthesizing hormone is not hyperemic.
• The elevated thyroglobulin confirms that the circulating hormone is spilling out of a thyroid unloading its stores rather than arriving from outside the patient, and the disproportionately modest total T3 beside a markedly high free T4 is what amiodarone's block of 5'-deiodinase conversion does to the ratio.
• Four years of exposure in a 66-year-old man is what makes the drug, rather than a coincidental autoimmune destructive thyroiditis, the explanation for the destruction: this is the epidemiology of amiodarone-induced disease, not of sporadic silent thyroiditis, and amiodarone-induced thyrotoxicosis develops in roughly 3% of treated patients in iodine-sufficient regions.
• Typing the disease picks the drug: type 2 responds to an oral glucocorticoid such as prednisone 40 mg daily, while a thionamide is useless because there is no ongoing synthesis to block. A beta blocker controls adrenergic symptoms in either type, and many patients later pass through a hypothyroid phase.
• In iodine-sufficient areas the 24-hour radioiodine uptake is low in both types, because the iodine load saturates the gland, so a low uptake confirms the setting but does not separate type 1 from type 2.

Why the others are wrong

• Type 1 amiodarone-induced thyrotoxicosis - type 1 is iodine substrate driving excess synthesis in a gland that already harbors autonomous nodules or latent Graves tissue, so it shows a palpable multinodular or diffusely enlarged goiter with preserved-to-increased Doppler flow; a normal-sized smooth gland with no flow at all is a gland that has stopped making hormone, not one that iodine has pushed into overproduction, and the undetectable TSH receptor antibodies remove the latent-Graves substrate as well. The added drug for type 1 would be a thionamide such as methimazole rather than a glucocorticoid (the trap is stopping at amiodarone plus thyrotoxicosis without subtyping).
• Painless (silent) lymphocytic thyroiditis - this is the one entity in the differential that no test result here separates from type 2 disease: it is also a painless destructive thyrotoxicosis with a normal-to-slightly-enlarged nontender gland, absent Doppler flow, low uptake, and an elevated thyroglobulin, and antibodies would not settle it either, since anti-thyroid peroxidase antibodies are positive in only about half of sporadic cases (about 80% in postpartum thyroiditis). The setting decides it: silent thyroiditis is classically postpartum or sporadic in younger women, whereas a 66-year-old man 4 years into amiodarone carries an exposure that explains follicular destruction directly, and type 2 disease is additionally treated with a glucocorticoid rather than managed supportively (the trap is stopping at destructive thyroiditis without asking what destroyed the gland).
• Exogenous (factitious) thyrotoxicosis - ingested thyroid hormone also produces thyrotoxicosis with a normal, painless, avascular gland, which is exactly why it belongs in this differential and why history alone cannot exclude it; it suppresses endogenous production, so serum thyroglobulin is low or undetectable rather than elevated, and ingested levothyroxine characteristically raises T4 out of proportion to T3 (the trap is reading a normal avascular gland as automatically factitious).
• Amiodarone-induced euthyroid hyperthyroxinemia - amiodarone's block of 5'-deiodinase commonly raises the free T4 in treated patients, so a high free T4 on this drug can look like an expected laboratory effect; but that benign pattern keeps the TSH normal or only transiently high and the T3 lowered, whereas a TSH below 0.01 mIU/L with an elevated total T3 and thyroglobulin, weight loss, and tremor is genuine thyrotoxicosis (the trap is dismissing every high free T4 on amiodarone as a drug artifact).

Additional high-yield points

• Thyroglobulin is elevated in both types of amiodarone-induced thyrotoxicosis and in silent thyroiditis, so it does not subtype the disease; its job is to separate hormone released from a thyroid from hormone swallowed by the patient.
• An iodine load can precipitate hyperthyroidism in a gland that carries latent Graves disease, but Graves disease drives the gland rather than destroying it and produces a diffusely enlarged, hypervascular thyroid with detectable TSH receptor antibodies; when an iodine load genuinely does unmask latent Graves tissue in an amiodarone-treated patient, the result is classified and managed as type 1 disease.
• Mixed and indeterminate forms are common, and when the gland exam and the Doppler study do not settle the type it is accepted practice to start methimazole and prednisone together and reassess in 2 to 4 weeks (European Thyroid Association 2018).
• Whether to stop amiodarone is a cardiology decision separate from which drug to add, and stopping helps slowly at best: the elimination half-life is roughly 50 to 100 days, so treatment is started regardless. Radioiodine ablation cannot be used in either type because uptake is too low for it to work.
• Amiodarone more often causes hypothyroidism, especially in iodine-sufficient regions, through a Wolff-Chaikoff effect the gland fails to escape; that is treated with levothyroxine and usually does not require stopping the drug.
• Do not confuse thyrotoxicosis with amiodarone's benign biochemical effect: by inhibiting 5'-deiodinase the drug commonly raises free T4 and lowers T3 with a normal or transiently high TSH. A suppressed TSH beside a frankly elevated T3, as here, is real thyrotoxicosis. Check TSH before starting amiodarone and about every 6 months thereafter.

Why Methimazole and propranolol is correct

• Exophthalmos, diffuse goiter, suppressed TSH, high free T4, and positive thyroid-stimulating immunoglobulin establish Graves disease.
• Initial therapy pairs a thionamide (methimazole), which blocks thyroid hormone synthesis, with a beta-blocker (propranolol) for adrenergic symptom control.
• Patients are rendered euthyroid before thyroidectomy to avoid precipitating thyroid storm, and methimazole pretreatment before radioactive iodine is advised for those at high risk from transient worsening (older age, cardiovascular disease, severe thyrotoxicosis).

Why the others are wrong

• Total thyroidectomy — a definitive option, but only after medical stabilization to euthyroid; a right-diagnosis-wrong-step sequencing trap.
• Potassium iodide solution — iodide (Lugol solution or SSKI) blocks stored hormone release and belongs in thyroid storm or in the roughly 10 days of preoperative preparation after a thionamide has been started; used as initial treatment it gives only transient control before escape and loads the gland with iodine, which blocks radioactive iodine therapy for weeks afterward.
• Radioactive iodine ablation — a first-line definitive option, but it can worsen active orbitopathy (exophthalmos is present here) and can transiently worsen hyperthyroidism, so starting a thionamide with a beta-blocker is the better initial step; the same sequencing trap.
• Propylthiouracil therapy — propylthiouracil blocks peripheral conversion of T4 to T3 as well as hormone synthesis, which makes it look like the stronger thionamide, but its risk of severe hepatotoxicity (an FDA boxed warning) limits it to the first trimester of pregnancy, thyroid storm, or a minor adverse reaction to methimazole in a patient who declines radioactive iodine or surgery, none of which is described here; the right-class-wrong-agent trap.